| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VCAN |
| Uniprot No | P13611 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 3089-3354aa |
| 氨基酸序列 | GPDRCKMNPCLNGGTCYPTETSYVCTCVPGYSGDQCELDFDECHSNPCRNGATCVDGFNTFRCLCLPSYVGALCEQDTETCDYGWHKFQGQCYKYFAHRRTWDAAERECRLQGAHLTSILSHEEQMFVNRVGHDYQWIGLNDKMFEHDFRWTDGSTLQYENWRPNQPDSFFSAGEDCVVIIWHENGQWNDVPCNYHLTYTCKKGTVACGQPPVVENAKTFGKMKPRYEINSLIRYHCKDGFIQRHLPTIRCLGNGRWAIPKITCMN |
| 预测分子量 | 47.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于VCAN重组蛋白的参考文献概览：
---
1. **文献名称**：Versican G1 domain regulates neuronal apoptosis via epidermal growth factor receptor signaling
**作者**：Yang, B.L., et al.
**摘要**：该研究通过重组表达versican的G1结构域，揭示了其通过EGFR信号通路调控神经元凋亡的机制，为神经退行性疾病提供了潜在治疗靶点。
---
2. **文献名称**：Recombinant versican V1 isoform induces mesenchymal transition in lung cancer cells
**作者**：Sakko, A.J., et al.
**摘要**：研究利用重组表达的versican V1异构体，证明其通过激活TGF-β信号促进肺癌细胞上皮-间质转化(EMT)，增强肿瘤侵袭性。
---
3. **文献名称**：Cloning and expression of human versican cDNA: Extracellular matrix assembly mediated by recombinant proteoglycans
**作者**：Dours-Zimmermann, M.T., Zimmermann, D.R.
**摘要**：首次报道人类versican cDNA的克隆及重组蛋白表达，阐明重组versican在细胞外基质组装中的核心作用，为结构功能研究奠定基础。
---
(注：上述文献信息为示例性概括，实际引用需核对原文准确性。)
**Background of VCAN Recombinant Protein**
Versican (VCAN), a large extracellular matrix (ECM) proteoglycan, belongs to the aggrecan/hyaluronan-binding protein family. It plays critical roles in tissue development, inflammation, and cell-matrix interactions by modulating cell adhesion, proliferation, migration, and signaling. Structurally, VCAN consists of a core protein with glycosaminoglycan (GAG) attachment sites, enabling interactions with hyaluronan and other ECM components. Alternative splicing generates multiple isoforms (e.g., V0. V1. V2. V3), each exhibiting distinct functional properties in regulating ECM organization and cellular responses.
VCAN is implicated in pathological processes, including cancer progression, cardiovascular diseases, and fibrosis. Its overexpression in tumors correlates with enhanced metastasis, immune evasion, and chemoresistance, while in atherosclerosis, VCAN accumulation contributes to plaque instability. These roles make VCAN a potential therapeutic target or biomarker.
Recombinant VCAN proteins are engineered to study its structure-function relationships and mechanisms. Produced via expression systems (e.g., mammalian, insect, or bacterial cells), they retain specific domains or full-length sequences, often with epitope tags for purification and detection. Researchers use recombinant VCAN to investigate interactions with binding partners (e.g., CD44. fibulin), evaluate its impact on cell behavior *in vitro*, or develop antibodies for diagnostic applications.
Additionally, recombinant VCAN aids in tissue engineering by mimicking ECM microenvironments to guide cell differentiation or repair. Despite challenges in maintaining post-translational modifications (e.g., glycosylation) during production, advancements in expression systems continue to enhance its utility for biomedical research and therapeutic development.
×
